Physician profile
Amy Q Wang
NPI 1720155609
$10,890.72
in general payments reported to CMS, 2019-2025
44 companies · $3,569 in 2025
The $3,569 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $406 · 2021: $546 · 2022: $1,036 · 2023: $1,981 · 2024: $3,059 · 2025: $3,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,104 · Long Term Medical Supply Or Device Loan: $2,164 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,103.93 |
| Long Term Medical Supply Or Device Loan | $2,163.62 |
| Education | $341.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,116.49 | 2022-2025 | Kisqali |
| Janssen Biotech, INC. | $1,559.62 | 2021-2025 | Imbruvica, Darzalex, Erleada |
| Celgene Corporation | $578.14 | 2019-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $531.81 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $399.95 | 2019-2025 | Opdivo, Reblozyl |
| Lilly USA, LLC | $399.72 | 2021-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $394.90 | 2020-2025 | |
| Astellas Pharma US INC | $390.48 | 2019-2023 | Xtandi |
| Incyte Corporation | $259.77 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $251.52 | 2021-2024 | Ninlaro, Iclusig |
| Pharmaessentia USA Corporation | $230.37 | 2022-2025 | Besremi |
| Eisai INC. | $204.68 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $197.29 | 2023-2025 | Onivyde, Tazverik, Somatuline Depot |
| Pharmacyclics LLC, An Abbvie Company | $181.89 | 2022-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $171.47 | 2024-2025 | Braftovi, Mektovi, Tukysa |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.